Shannon Sweeney, APRN
Nurse Practitioner, Surgery (Cardiac)Cards
About
Research
Publications
2026
The benefits of investments to combat HIV, tuberculosis, and malaria for primary healthcare from 2000 to 2023: An economic modeling analysis
Su J, Stover J, Pretorius C, Winskill P, Sweeney S, Hallett T, Menzies N. The benefits of investments to combat HIV, tuberculosis, and malaria for primary healthcare from 2000 to 2023: An economic modeling analysis. PLOS Medicine 2026, 23: e1005036. PMID: 41950262, PMCID: PMC13061260, DOI: 10.1371/journal.pmed.1005036.Peer-Reviewed Original ResearchConceptsPrimary healthcare utilizationHigh-burden settingsPrimary healthcareRoutine health systemEconomic model analysisSymptomatic HIVPHC visitsMalariaHIVInpatient bed daysTuberculosisMiddle-income countriesBed daysAverted costsPrimary healthcare servicesSub-Saharan AfricaLow-income countriesDiseaseHospital bed capacityPublished unit costsHealth systemGovernment health spendingHealth gainsBenefits of investmentBed capacityCost-effectiveness of cancer interventions in Rwanda: literature review and expert elicitation for health benefits package design
Nemzoff C, Madriz-Montero A, Mumukunde I, Sindambiwe J, de Valois Ndishimye I, Uyisabye V, Humuza J, Baltussen R, Hitimana R, Sweeney S, Umuhoza S, Vassall A. Cost-effectiveness of cancer interventions in Rwanda: literature review and expert elicitation for health benefits package design. BMJ Public Health 2026, 4: e003718. PMID: 41808901, PMCID: PMC12970044, DOI: 10.1136/bmjph-2025-003718.Peer-Reviewed Original ResearchHealth benefit package designHealth benefits packageCost-effectiveness ratioCost-effectiveness evidence baseEvidence baseCost-effective assessmentCancer interventionHealth technology assessment approachMiddle-income countriesBenefit package designCost-effectiveness ratio estimatesCost-effectiveCost-effectiveness findingsCancer servicesHealth servicesPreventive interventionsEvidence gapsTechnology assessment approachDisease burdenBenefit packageInterventionGovernment of RwandaExpert elicitationHealthLiterature reviewInforming policy through evidence: A scoping review of factors that influence enrolment in community-based health insurance in East Africa
Lubajo R, Sweeney S, Olu O. Informing policy through evidence: A scoping review of factors that influence enrolment in community-based health insurance in East Africa. Global Health Research And Policy 2026, 11: 8-19. PMID: 41908075, PMCID: PMC13017189, DOI: 10.1016/j.ghrp.2026.01.002.Peer-Reviewed Original ResearchConceptsCommunity-based health insuranceCommunity-based health insurance schemeDeterminants of enrolmentAttainment of universal health coverageCommunity-based health insurance enrollmentHealth insuranceSocio-ecological model frameworkScoping Reviews checklistCommunity-level determinantsSocio-ecological levelsUniversal health coveragePreferred Reporting ItemsMiddle-income countriesMixed-methods designBenefit package designEnglish-language studiesEast AfricaHealthcare accessReferral systemScoping ReviewHealth coverageReview checklistThematic analysisReporting ItemsSocio-Demographic
2025
Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis
Kim C, Sweeney S, Sohn H, Knight G, McQuaid C. Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis. PLOS Global Public Health 2025, 5: e0005275. PMID: 41100518, PMCID: PMC12530546, DOI: 10.1371/journal.pgph.0005275.Peer-Reviewed Original ResearchDrug susceptibility testingRifampicin-resistant tuberculosisMDR/RR-TBFluoroquinolone resistanceInitial treatmentResistance prevalenceEmpirical useFluoroquinolone resistance ratesEfficacy of moxifloxacinTreatment of multidrug-Incremental cost-effectiveness ratioMarkov cohort modelCost-effectiveness ratioEmpirical treatmentSusceptibility testingResistance ratesFluoroquinolone antibiotic moxifloxacinTreatment efficacyBurden countriesDisability-adjusted life yearsWHO recommendationsBPaLLife yearsAntibiotic moxifloxacinMoxifloxacinImplications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis
Can M, Sweeney S, Allwood B, Dorman S, Cohen T, Menzies N. Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis. The Lancet Global Health 2025, 13: e1240-e1249. PMID: 40580989, PMCID: PMC12364304, DOI: 10.1016/s2214-109x(25)00114-7.Peer-Reviewed Original ResearchConceptsLifetime health lossPost-tuberculosis sequelaeHIV prevalence settingsProgressive lung damageLifetime health consequencesPrompt treatmentUS National InstitutesLung damageDelayed TreatmentPrevalence settingsNo treatmentLifetime health outcomesHealth benefitsLife expectancy lossConsequence of tuberculosisHealth effectsHigher mortality riskTuberculosis treatmentInitiation of tuberculosis treatmentLifetime disease burdenBenefits of prompt treatmentUS National Institutes of HealthDelayed initiationNational Institutes of HealthUntreated pulmonary tuberculosisSelecting Cost-Effectiveness Methods for Health Benefits Package Design: A Systematic Approach
Nemzoff C, Sweeney S, Baltussen R, Vassall A. Selecting Cost-Effectiveness Methods for Health Benefits Package Design: A Systematic Approach. International Journal Of Health Policy And Management 2025, 14: 1-9. PMID: 40767209, PMCID: PMC12089834, DOI: 10.34172/ijhpm.8562.Peer-Reviewed Original ResearchHealth benefits packageCost-effectiveness analysisHealth technology assessmentHealth benefit package designBenefit package designFollow-up surveyCost-effectiveCost-effectiveness analysis methodsCost-effectiveness modelHealth economicsLiterature reviewGlobal evidenceBenefit packageHealthPublic healthTechnology assessmentAssessment methodsSurvey of authorsExpert opinionMethod selectionPrioritization criteriaExtensive investmentLocal designAssess CEAssessment24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation
Sweeney S, Laurence Y, Berry C, Singh M, Dodd M, Fielding K, Kazounis E, Moodliar R, Solodovnikova V, Tigay Z, Liverko I, Parpieva N, Butabekov I, Usmanova R, Rassool M, Motta I, Nyangweso G, Jolivet P, Abdrasuliev T, Moe S, Aw P, Samieva N, Nyang'wa B. 24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. The Lancet Global Health 2025, 13: e355-e363. PMID: 39890235, DOI: 10.1016/s2214-109x(24)00467-4.Peer-Reviewed Original ResearchConceptsStandard of careRifampicin-resistant tuberculosisPatient-incurred costsHealth systemStandard-of-care regimensTreatment of rifampicin-resistant tuberculosisWeeks of follow-upAll-oral regimensReduce pill burdenImprove treatment efficacyTuberculosis treatment regimensCost-savingProbabilistic sensitivity analysesBurden of tuberculosisEconomic evaluationDegrees of cost savingsInpatient bed daysTrial-based evidenceEfficacy endpointCost dataRegimen groupPill burdenDrug regimensTreatment regimensUnfavourable outcomeFactors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis.
Kim S, Can M, Agizew T, Auld A, Balcells M, Bjerrum S, Dheda K, Dorman S, Esmail A, Fielding K, Garcia-Basteiro A, Hanrahan C, Kebede W, Kohli M, Luetkemeyer A, Mita C, Reeve B, Silva D, Sweeney S, Theron G, Trajman A, Vassall A, Warren J, Yotebieng M, Cohen T, Menzies N. Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-analysis. PLOS Medicine 2025, 22: e1004502. PMID: 39804959, PMCID: PMC11729971, DOI: 10.1371/journal.pmed.1004502.Peer-Reviewed Original ResearchConceptsIndividual Patient Data Meta-AnalysisPatient data meta-analysisTreatment initiationData Meta-AnalysisBacteriological test resultsTB treatmentFactors associated with treatment initiationMultiple factors influence decisionsAssociated with treatment initiationTuberculosis treatment initiationMeta-analysisNegative test resultsPositive test resultsFactors influence decisionsHIV infectionPulmonary tuberculosisSmear microscopyNight sweatsClinical examinationMale sexClinical criteriaHierarchical Bayesian logistic regressionCohort studySystematic reviewTreatment decisions
2024
Estimating the health and macroeconomic burdens of tuberculosis in India, 2021–2040: A fully integrated modelling study
Keogh-Brown M, Sumner T, Sweeney S, Vassall A, Jensen H. Estimating the health and macroeconomic burdens of tuberculosis in India, 2021–2040: A fully integrated modelling study. PLOS Medicine 2024, 21: e1004491. PMID: 39666614, PMCID: PMC11637336, DOI: 10.1371/journal.pmed.1004491.Peer-Reviewed Original ResearchConceptsGross domestic productMacroeconomic burdenCumulative gross domestic productReturn to investmentHigh-income householdsLow-income householdsDomestic productEconomic growthReduction targetsIndian economyEconomic gainsInvestmentEconomic impactEconomyCountriesHouseholdsBurden of TBEconomic burdenDisease burdenFundingImpact of TBLarge healthCase detectionTB-related deathsProvisionImproving hospital-based opioid substitution therapy (iHOST): protocol for a mixed-methods evaluation
Lewer D, Brown M, Burns A, Eastwood N, Gittins R, Holland A, Hope V, Ko A, Lewthwaite P, Morris A, Noctor A, Preston A, Scott J, Smith E, Sweeney S, Tilouche N, Wickremsinhe M, Harris M. Improving hospital-based opioid substitution therapy (iHOST): protocol for a mixed-methods evaluation. NIHR Open Research 2024, 4: 10. PMID: 39568556, PMCID: PMC11576563, DOI: 10.3310/nihropenres.13534.2.Peer-Reviewed Original ResearchOpioid substitution therapyProcess evaluationPatient-directed dischargeAssociated with improved healthQualitative process evaluationHospital-based servicesHealth research projectsMixed-methods evaluationQuasi-experimental quantitative studyDifference-in-differences analysisMixed-methods studyOnline training moduleSubstitution therapyAdmitted to hospitalControl hospitalsAcute hospitalsImprove careOpioid withdrawalHospital cliniciansEmergency readmissionIllicit opioidsHospital staffQuantitative studyFocus groupsClinical guidelines